Prelude Highlights Continued Strength of Discovery Engine at 2024 AACR Annual Meeting
Highly selective oral SMARCA2 degrader, PRT7732, shows robust anti-tumor activity in vivo as monotherapy and in combination with chemotherapy, at […]
Highly selective oral SMARCA2 degrader, PRT7732, shows robust anti-tumor activity in vivo as monotherapy and in combination with chemotherapy, at […]
DALLAS, April 09, 2024 (GLOBE NEWSWIRE) — Applied Digital Corporation (Nasdaq: APLD) (“Applied Digital” or the “Company”), a designer, builder […]
ANDOVER, Mass., April 09, 2024 (GLOBE NEWSWIRE) — Vicor Corporation (NASDAQ: VICR) announced today it will hold its first quarter […]
BEIJING, April 09, 2024 (GLOBE NEWSWIRE) — Jianzhi Education Technology Group Company Limited (the “Company” or “Jianzhi”) (NASDAQ: JZ), a […]
DALLAS, April 09, 2024 (GLOBE NEWSWIRE) — Veritex Holdings, Inc. (Nasdaq: VBTX) (“Veritex” or “the Company”), the parent holding company […]
THE WOODLANDS, Texas, April 09, 2024 (GLOBE NEWSWIRE) — ChampionX Corporation (“ChampionX” or the “Company”) (NASDAQ: CHX) announced today that […]
– Preclinical data supports potential for proprietary nsCAR platform to selectively eliminate cancer cells while preserving healthy tissue – Gamma-delta […]
CHARLOTTE, N.C., April 09, 2024 (GLOBE NEWSWIRE) — DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the “Company”) (Nasdaq: XRAY) today announced […]
100% reduction of target lesions in one melanoma and one pancreatic cancer patient observed among 4 Partial Responses (PR) to […]
NEWPORT NEWS, Va., April 09, 2024 (GLOBE NEWSWIRE) — Global engineering and defense technologies provider HII (NYSE: HII) was recognized […]